Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2016-08-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with fludarabine/treosulfan

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

NCT00603954

Hematological Malignancies

COMPLETED PHASE2

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

NCT00553098

Immunodeficiency Syndrome Non-Cancer Diagnosis

COMPLETED PHASE2

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

NCT03615105

Acute Lymphoid Leukemia (ALL) Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) +3 more

TERMINATED PHASE2

Immune Disorder HSCT Protocol

NCT01821781

Immune Deficiency Disorders Severe Combined Immunodeficiency Chronic Granulomatous Disease +11 more

RECRUITING PHASE2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Acute Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia +25 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients Receiving Mismatched Allogeneic HCT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

immunosuppression

Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for mismatched allogeneic HCT
* Unrelated donor with maximal 2 antigen or allelic mismatches in HLA-I or HLA-II
* Age \>=75, \>=18 years
* Patients Age \<=50 if a HCT-CI score \> 2 \[acc. to Sorror et al., 2005\]
* Karnofsky Index \>60%
* Patients with:

* Acute myeloid leukemia in CR (\<5% blasts)
* Acute lymphoblastic leukemia in CR (\< 5% blasts)
* Myelodysplastic syndrome with up to 20% blasts
* Osteomyelofibrosis
* Chronic lymphocytic leukemia
* High grade Non-Hodgkin Lymphoma in CR or PR
* Low grad Non-Hodgkin Lymphoma in CR or PR
* M. Hodgkin in CR or PR
* Chronic myeloid leukaemia in chronic phase or CR of blast crisis

Exclusion Criteria

* Patients with \>5% blasts in BM at the time of transplantation
* Progressive or chemorefractory disease
* Less than 3 months after preceding HCT
* CNS involvement with disease
* Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month.
* Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher 2x upper limit of normal.
* Chronic active viral hepatitis
* Ejection fraction \<40 % on echocardiography
* Patients with \> grade II hypertension by CTC criteria
* Creatinine clearance \<50 ml/min
* Proteinuria \>800 mg/24 h
* Respiratory failure necessitating supplemental oxygen or DLCO \<30%
* Allergy against murine antibodies
* Known allergy/intolerance against sirolimus or one of it's excipients
* HIV-Infection
* Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter. (Women of childbearing potential must have a negative serum pregnancy test at study entry)
* Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
* Patients with a history of psychiatric illness or condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
* Patients unwilling or unable to comply with the protocol
* Unable to give informed consent
* Enrollment in an other trial interfering with the endpoints of this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No